Optimizing Surrogate Matrix Selection for Endogenous Biomarker LC-MS/MS Quantitation Assays
Historically, LC-MS/MS focused on synthetic drug pharmacokinetics. However, improved sensitivity now allows the analysis of endogenous biomarkers (lipids, proteins, etc.) previously reserved for Ligand Binding Assays (LBA). A primary challenge in biomarker bioanalysis is that these compounds are endogenous to biological matrices, and the matrix could present challenging physicochemical properties. Unlike conventional drug testing, there is no true blank matrix available to build calibration standards. To quantify these levels accurately, researchers must develop a surrogate matrix that mimics the behavior of authentic patient samples without the background interference of the natural analyte. Selecting and validating this surrogate is the most critical step in establishing a reliable LC-MS/MS method for any naturally occurring compound.
Download our poster, recently presented at WRIB 2026 to learn more.
Advanced Bioanalytical Support for Oligonucleotides
Aliri has supported 5 of the 20 approved OGNs on market as they transitioned from preclinical to clinical to FDA approval Aliri is proud to be a trailblazer in the bioanalysis of RNAi therapeutics with significant experience supporting the development of oligonucleotides, which includes siRNAs, ASOs, PPMOs, ARCs/AOCs, and other RNAi conjugates.
Our tenured team of scientists are continuously innovating and adapting our methodologies for improved
assay sensitivity and specificity to deliver accurate and reliable data to our sponsors.
This has led to the critical application and optimization of available analytical approaches, including novel SPE and hybridization extraction techniques that can achieve subnanogram per milliter LLOQ’s with the
specificity of LC/MS detection.
Download the fact sheet to learn more.
Ready-to-Use Biomarker Panels: Oncology Collection
From tumor initiation to therapeutic response, oncology research increasingly depends on biomarker data that must be robust, translatable, and clinically meaningful. Clinicians and translational teams now require the simultaneous assessment of an expanding number of biomarkers to better capture tumor heterogeneity, mechanisms of resistance, and patient response to therapy.
To expedite your research and minimize development costs, we have translated our years of oncology biomarker expertise into 24 ready-to-use panels. These panels are designed to address key oncology questions that are critical for understanding disease biology and therapeutic response, including for example:
- Tumor characterization
- Immune contexture
- Pathway activation
- Target engagement
- Patient Stratification
Download the brochure to view a full list of panels and biomarkers in our Oncology Collection.
Ready-to-Use Biomarker Panels: Immunology & Inflammation Collection
From disease onset to therapeutic response, Immunology and Inflammation research increasingly relies on biomarker data that must be robust, translatable, and biologically meaningful. Clinicians and translational teams now require the simultaneous assessment of growing numbers of biomarkers to better capture disease complexity, patient heterogeneity, and treatment response.
To expedite your research and minimize development costs, we have translated our years of immunology and inflammatory biomarker expertise into 23 ready-to-use panels. These panels are designed to address key disease-relevant questions about disease onset, progression, and response to therapy, including for example:
- Immune cell activation and differentiation
- Cytokine and chemokine signaling
- Tissue inflammation
- Pathway dysregulation
- Patient stratification
Download the brochure to view a full list of panels and biomarkers in our Immunology & Inflammation Collection.
ABCs of ADCs: From PK to PD
Predictive bioanalytical strategies for the development of Antibody-Drug Conjugates (ADCs)
ADCs often fail because the drug gets to the right tissue, but misses its target. It’s not enough to just seek the concentration of your ADC in the tissue, you need to know its exact location to predict efficacy and move your development program forward with confidence. In this webinar, renowned scientists and industry thought leaders Troy Voelker and Corinne Ramos outline a holistic bioanalytical strategy for your ADC, incorporating traditional bioanalysis with spatial bioanalysis to reveal decision-making data about how your ADC engages with the complex microenvironment.
- Antibody payload concentration
- Conjugated antibody concentration
- Free payload concentration
- Spatial distribution
- Target engagement
- Toxicity
The Complexity of the Gastrointestinal Tract: A Multilayered Challenge for Drug and Biomarker Studies
The gastrointestinal (GI) tract is a highly specialized and dynamic system, playing a central role in digestion, absorption, immune response, and microbiome interaction. From the stomach to the small intestine (duodenum, jejunum, ileum) and the large intestine (colon, rectum), each segment presents unique physiological and structural characteristics that influence drug delivery and disease progression.
Aliri’s spatial imaging capabilities allows you to understand drug behavior and biomarker expression across the four main layers of the intestinal wall.
Download the fact sheet to learn more.
Oligonucleotide Hybridization LCMS Workflows and Probe Optimization
In this scientific poster recently presented at EBF Open Symposium, we investigated the biodistribution and potential toxicity of lipid nanoparticles (LNP1 and LPN2), which are crucial carriers for mRNA-based treatments after administration to male and female mice, analyzing their distribution in whole-body carcasses and specific organs using MALDI-MSI.
Download our poster to learn more.
Mapping mRNA–Lipid Nanoparticle Distribution in Mouse Whole Body and Organs by MALDI-MSI
In this scientific poster recently presented at EBF Open Symposium, we investigated the biodistribution and potential toxicity of lipid nanoparticles (LNP1 and LPN2), which are crucial carriers for mRNA-based treatments after administration to male and female mice, analyzing their distribution in whole-body carcasses and specific organs using MALDI-MSI.
Download our poster to learn more.
Ring Trial Study Results for Oligonucleotides Prove Hybridization LC-MS Approach Superior to LBA in Achieving Lower Detection Limits and Higher Specificity
Aliri was recently one of 10 labs to participate in the Oligonucleotide Ring Trial, in which industry experts joined together to evaluate the effectiveness of LC-MS, LBA, and qPCR when quantifying the concentrations of oligonucleotide in biological samples. This first-of-its-kind study aimed to give clarity to drug developers about the methodology best suited for future development programs. Specifically, the Ring Trial focused on three types of oligonucleotides, an ASO (Fomivirsen), a GalNAc-siRNA (Lumasiran), and a PMO (Viltolarsen).
Troy Voelker, Sr. Lab Director at Aliri and Chair of the AAPS Oligonucleotide Discussion Group, led the LC-MS method development of the PMO (Viltolarsen), which was analyzed using three mass spectrometry platforms: a QExactive, a time-of-flight (TOF), and a triple quadrupole instrument. In this presentation, he reveals exciting data that proves hybridization LC-MS superior to LBA in achieving lower detection limits and higher specificity.
Download the presentation to read the study findings.
Enabling Clinical Adoption of Omics: Fit-for-Purpose Validation and a Spatial Biomarker Case Study
Over the past two decades, omics technologies have steadily expanded from discovery research into translational and clinical development, offering unprecedented insights into biology, disease mechanisms, and therapeutic response. Advances in genomics, transcriptomics, proteomics, metabolomics, and, more recently, spatial and multi-omics platforms have created powerful opportunities to identify predictive biomarkers, refine patient stratification, and accelerate drug development. The added value of omics lies in their ability to capture complex, system-level biology that traditional single-analyte assays cannot address, thereby bridging the gap between exploratory research and precision medicine.
Yet this rapid progress has also highlighted a critical challenge: how to validate omics data in a way that is scientifically rigorous but also practical. Current analytical validation paradigms were largely developed for conventional assays such as ELISA or qPCR, which measure one or a handful of targets at a time. Applying the same frameworks directly to high-dimensional omics assays often results in processes that are overly burdensome, expensive, and poorly aligned with the dynamic nature of omics platforms.
Moving forward, the field needs more efficient and adaptive validation processes, aligned with the specific purpose of each omics application. This involves applying full rigor when data will inform regulatory submissions or clinical decisions, while using streamlined, fit-for-purpose approaches for exploratory research and mechanistic studies.
In this presentation, Aliri R&D Director and Spatial-Omics Expert, Corinne Ramos, Ph.D., illustrates these challenges and opportunities through a spatial multi-omics use case, where paired patient biopsies were profiled with spatial transcriptomics and proteomics to uncover mechanistic insights, identify predictive biomarkers, and generate regulatory-ready evidence for clinical development.
Download the presentation to learn more.